𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cytotoxic In vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy effects of activation with recombinant interleukin-2

✍ Scribed by Cristina Feruglio; Renato Zambello; Livio Trentin; Pietro Bulian; Tiziano Franceschi; Gian Luigi Cetto; Gianpietro Semenzato

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
658 KB
Volume
69
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thirteen-year, long-term efficacy of int
Thirteen-year, long-term efficacy of interferon 2α and interleukin 2-based home therapy in patients with advanced renal cell carcinoma
✍ Jens Atzpodien; Reinhard Hoffmann; Marcus Franzke; Christian Stief; Thomas Wande 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Background: The goal of the current report was to demonstrate the long-term efficacy of outpatient subcutaneous (sc) interferon alpha (ifn-alpha) and sc interleukin 2 (il-2)-based combination regimens in patients with metastatic renal cell carcinoma. ## Methods: In three consecutive clinical t

A Phase II trial of intravenous gemcitab
A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH

A phase I study of recombinant human int
A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma
✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

Subcutaneous interleukin-2 and interfero
Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie
✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a